Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease

被引：63

作者：

Abenavoli, Ludovico ^{[1
]}

Falalyeyeva, Tetyana ^{[2
]}

Boccuto, Luigi ^{[3
,4
]}

Tsyryuk, Olena ^{[2
]}

Kobyliak, Nazarii ^{[5
]}

机构：

[1] Magna Graecia Univ Catanzaro, Dept Hlth Sci, I-8810 Catanzaro, Italy

[2] Taras Shevchenko Natl Univ Kyiv, Sch Med, Volodymyrska St 64-13, UA-01601 Kiev, Ukraine

[3] Greenwood Genet Ctr, Greenwood, SC 29646 USA

[4] Clemson Univ, Sch Hlth Res, Clemson, SC 29646 USA

[5] Bogomolets Natl Med Univ, Dept Endocrinol, Pushkinska 22a, UA-01610 Kiev, Ukraine

来源：

PHARMACEUTICALS | 2018年 / 11卷 / 04期

关键词：

nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; fibrosis; obeticholic acid; farnesoid X receptor; metabolism; FARNESOID-X-RECEPTOR; HEPATIC STEATOSIS; AGONIST; FXR; HYPERTENSION; INFLAMMATION; ELAFIBRANOR; PROBIOTICS; REDUCTION; PROTECTS;

D O I：

10.3390/ph11040104

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The main treatments for patients with nonalcoholic fatty liver disease (NAFLD) are currently based on lifestyle changes, including ponderal decrease and dietary management. However, a subgroup of patients with nonalcoholic steatohepatitis (NASH), who are unable to modify their lifestyle successfully, may benefit from pharmaceutical support. Several drugs targeting pathogenic mechanisms of NAFLD have been evaluated in clinical trials for the treatment of NASH. Farnesoid X receptor (FXR) is a nuclear key regulator controlling several processes of the hepatic metabolism. NAFLD has been proven to be associated with abnormal FXR activity. Obeticholic acid (OCA) is a first-in-class selective FXR agonist with anticholestatic and hepato-protective properties. Currently, OCA is registered for the treatment of primary biliary cholangitis. However, promising effects of OCA on NASH and its metabolic features have been reported in several studies.

引用

页数：10

共 53 条

[1] Effect of Mediterranean Diet and Antioxidant Formulation in Non-Alcoholic Fatty Liver Disease: A Randomized Study [J].

Abenavoli, Ludovico ;

Greco, Marta ;

Milic, Natasa ;

Accattato, Francesca ;

Foti, Daniela ;

Gulletta, Elio ;

Luzza, Francesco .

NUTRIENTS, 2017, 9 (08)

[2] Metabolic aspects of adult patients with nonalcoholic fatty liver disease [J].

Abenavoli, Ludovico ;

Milic, Natasa ;

Di Renzo, Laura ;

Preveden, Tomislav ;

Medic-Stojanoska, Milica ;

De Lorenzo, Antonino .

WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (31) :7006-7016

[3] Effects of Mediterranean diet supplemented with silybin-vitamin E-phospholipid complex in overweight patients with non-alcoholic fatty liver disease [J].

Abenavoli, Ludovico ;

Greco, Marta ;

Nazionale, Immacolata ;

Peta, Valentina ;

Milic, Natasa ;

Accattato, Francesca ;

Foti, Daniela ;

Gulletta, Elio ;

Luzza, Francesco .

EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2015, 9 (04) :519-527

[4] Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis [J].

Adorini, Luciano ;

Pruzanski, Mark ;

Shapiro, David .

DRUG DISCOVERY TODAY, 2012, 17 (17-18) :988-997

[5]

Albanis E., 2005, HEPATOLOGY, V42, p1040A

[6] Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial [J].

Armstrong, Matthew J. ;

Barton, Darren ;

Gaunt, Piers ;

Hull, Diana ;

Guo, Kathy ;

Stocken, Deborah ;

Gough, Stephen C. L. ;

Tomlinson, Jeremy W. ;

Brown, Rachel M. ;

Huebscher, Stefan G. ;

Newsome, Philip N. .

BMJ OPEN, 2013, 3 (11)

[7] Partial directly observed therapy with ombitasvir/paritaprevir based regimens allows for successful treatment of patients on daily supervised methadone [J].

Boyle, A. ;

Marra, F. ;

Fox, R. ;

Morris, J. ;

Fleming, C. ;

Reilly, E. ;

Heydtmann, M. ;

Cairns, H. ;

Barclay, S. T. .

JOURNAL OF HEPATOLOGY, 2017, 66 (01) :S282-S282

[8] The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD) [J].

Buzzetti, Elena ;

Pinzani, Massimo ;

Tsochatzis, Emmanuel A. .

METABOLISM-CLINICAL AND EXPERIMENTAL, 2016, 65 (08) :1038-1048

[9] The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases [J].

Chalasani, Naga ;

Younossi, Zobair ;

Lavine, Joel E. ;

Charlton, Michael ;

Cusi, Kenneth ;

Rinella, Mary ;

Harrison, Stephen A. ;

Brunt, Elizabeth M. ;

Sanyal, Arun J. .

HEPATOLOGY, 2018, 67 (01) :328-357

[10] FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats [J].

Cipriani, Sabrina ;

Mencarelli, Andrea ;

Palladino, Giuseppe ;

Fiorucci, Stefano .

JOURNAL OF LIPID RESEARCH, 2010, 51 (04) :771-784

← 1 2 3 4 5 6 →